RTTNews | Mar 15, 2021 07:09AM EDT

07:08 Monday, March 15, 2021 (RTTNews.com) - AVEO Oncology (AVEO) said it will regain rights to AV-203 outside of North America, the company's clinical-stage potent humanized IgG1 monoclonal antibody that targets ErbB3, following the voluntary termination of its collaboration and license agreement by CANbridge Life Sciences. Under the 2016 agreement, AVEO granted CANbridge Life Sciences worldwide rights, excluding the United States, Canada, and Mexico, to AV-203.

"By reacquiring rights to AV-203 outside of North America, we add global rights to a third IgG1 antibody clinical candidate within our internally developed and diverse portfolio of oncology therapeutics," said Michael Bailey, CEO of AVEO.

Read the original article on RTTNews ( https://www.rttnews.com/3177364/aveo-to-regain-rights-to-av-203-in-all-territories-outside-of-north-america.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved